U.S. Markets closed

Need To Know: Genocea Biosciences, Inc. (NASDAQ:GNCA) Insiders Have Been Buying Shares

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So we'll take a look at whether insiders have been buying or selling shares in Genocea Biosciences, Inc. (NASDAQ:GNCA).

What Is Insider Selling?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock on the market. However, rules govern insider transactions, and certain disclosures are required.

Insider transactions are not the most important thing when it comes to long-term investing. But logic dictates you should pay some attention to whether insiders are buying or selling shares. For example, a Columbia University study found that 'insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers'.

Check out our latest analysis for Genocea Biosciences

The Last 12 Months Of Insider Transactions At Genocea Biosciences

In the last twelve months, the biggest single purchase by an insider was when Chairman of Scientific Advisory Board & Director George Siber bought US$100k worth of shares at a price of US$4.96 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$3.48). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

Happily, we note that in the last year insiders bought 21675 shares for a total of US$106k. In the last twelve months Genocea Biosciences insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

NasdaqCM:GNCA Recent Insider Trading, June 24th 2019

Genocea Biosciences is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does Genocea Biosciences Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our information indicates that Genocea Biosciences insiders own about US$220k worth of shares. We might be missing something but that seems like very low insider ownership.

So What Does This Data Suggest About Genocea Biosciences Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. The transactions are fine but it'd be more encouraging if Genocea Biosciences insiders bought more shares in the company. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Genocea Biosciences.

Of course Genocea Biosciences may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.